Assignee
MEREO BIOPHARMA 3 LTD
GB·2 granted patents·8 pending applications·3 citations·filing 2017–2024
Top patents by PatentIndex Score
10 records- 0178US10961305B2Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2017·Granted Mar 30, 2021·3 cites·19 claims
- 0274US2024400666A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2024·Application pending·0 cites
- 0371US2023365669A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2023·Application pending·0 cites
- 0469US2025122273A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2024·Application pending·0 cites
- 0561US2021253684A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2020·Application pending·0 cites
- 0659US12173058B2Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2021·Granted Dec 24, 2024·0 cites·11 claims
- 0757US2020123242A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2020·Application pending·0 cites
- 0852US2020179509A1Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2017·Application pending·0 cites
- 0945US2025011407A1Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfectaMEREO BIOPHARMA 3 LTD·Filed 2022·Application pending·0 cites
- 1037US2021198350A1Use of a sclerostin antagonistMEREO BIOPHARMA 3 LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MEREO BIOPHARMA 3 LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →